At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A new drug called lepodisiran may offer hope to millions of people at risk of heart attacks and strokes by targeting a little ...

President Trump wants to bring pharmaceutical manufacturing back to the U.S. Experts warn tariffs could result in shortages ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...